Herpes Simplex Virus

Chapter

Abstract

Our understanding of human herpes simplex virus (HSV) has increased tremendously since the early descriptions of disease provided by Hippocrates [1, 2]. Notable advances include the correlation of herpetic lesions with genital infections in the eighteenth century [3] and Vidal’s recognition of human-to-human transmission in 1893 [2]. Antigenic differences between HSV subtypes, suspected on clinical observations by Lipschitz [4], were confirmed in 1968 [5]. In modern day, there is successful antiviral treatment available for most HSV infections [6]. Insight into the viral life cycle and gene expression has been a driving force behind the development of antiviral treatment, including new vaccines and gene therapy [4].

Keywords

Placebo Transportation Dehydration Dermatitis Thymidine 

References

  1. 1.
    Beswick TS. The origin and the use of the word herpes. Med Hist. 1962;6:214–32.PubMedCrossRefGoogle Scholar
  2. 2.
    Roizman B, Whitley RJ. The nine ages of herpes simplex virus. Herpes. 2001;8:23–7.PubMedGoogle Scholar
  3. 3.
    Hutfield DC. History of herpes genitalis. Br J Vener Dis. 1966;42:263–8.PubMedGoogle Scholar
  4. 4.
    Tyring SK, Yen-Moore A, Lupi O. Mucocutaneous manifestations of viral diseases. London: Informa Healthcare; 2010. p. 65–97.CrossRefGoogle Scholar
  5. 5.
    Nahmias AJ, Dowdle WR. Antigenic and biologic differences in herpesvirus hominis. Prog Med Virol. 1968;10:110–59.PubMedGoogle Scholar
  6. 6.
    Arvin A, Roizman B, Whitley R, Mocarski E, Campadelli-Fiume G, Yamanishi K, editors. Human herpes-virus: biology, therapy & immunoprophylaxis. Cambridge: Cambridge University Press; 2007.Google Scholar
  7. 7.
    El Hayderi L, Raty L, Failla V, Caucanas M, Paurobally D, Nikkels AF. Severe herpes simplex virus type-I infections after dental procedures. Med Oral Patol Oral Cir Bucal. 2011; 16(1):e15–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Lin H, He N, Su M, Feng J, Chen L, Gao M. Herpes simplex virus infections among rural residents in eastern China. BMC Infect Dis. 2011;11:69.PubMedCrossRefGoogle Scholar
  9. 9.
    Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296(8):964–73.PubMedCrossRefGoogle Scholar
  10. 10.
    Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis. 2002;186 Suppl 1:S3–28.PubMedCrossRefGoogle Scholar
  11. 11.
    Wheeler Jr CE. The herpes simplex problem. J Am Acad Dermatol. 1988;18:163–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Glezen WP, Fernald GW, Lohr JA. Acute respiratory disease of university students with special reference to the etiologic role of Herpesvirus hominis. Am J Epidemiol. 1975;101(2):111–21.PubMedGoogle Scholar
  13. 13.
    McMillan JA, Weiner LB, Higgins AM, Lamparella VJ. Pharyngitis associated with herpes simplex virus in college students. Pediatr Infect Dis J. 1993;12(4):280–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Young SK, Rowe NH, Buchanan RA. A clinical study for the control of facial mucocutaneous herpes virus infections. I. Characterization of natural history in a professional school population. Oral Surg Oral Med Oral Pathol. 1976;41:498–507.PubMedCrossRefGoogle Scholar
  15. 15.
    Spruance SL, Overall Jr JC, Kern ER, Krueger GG, Pliam V, Miller W. The natural history of recurrent herpes simplex labialis: implications for antiviral therapy. N Engl J Med. 1977; 297:69–75.PubMedCrossRefGoogle Scholar
  16. 16.
    Daniels CA, LeGoff SG. Shedding of infectious virus/antibody complexes from vesicular lesions of patients with recurrent herpes labialis. Lancet. 1975;2:524–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Spruance SL. Pathogenesis of herpes simplex labialis: excretion of virus in the oral cavity. J Clin Microbiol. 1984;19(5):675–9.PubMedGoogle Scholar
  18. 18.
    Buddingh GJ, Schrum DI, Lanier JC, Guidry DJ. Studies of the natural history of herpes simplex infections. Pediatrics. 1953;11:595–610.PubMedGoogle Scholar
  19. 19.
    Simmons A. Clinical manifestations and treatment considerations of herpes simplex virus infection. J Infect Dis. 2002;186 Suppl 1:S71–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Shiley K, Blumberg E. Herpes viruses in transplant recipients: HSV, VZV, human herpes viruses, and EBV. Infect Dis Clin North Am. 2010;24:373–93.PubMedCrossRefGoogle Scholar
  21. 21.
    Corey L, Wald A. Maternal and neonatal herpes simplex virus infections. N Engl J Med. 2009;361:1376–85.PubMedCrossRefGoogle Scholar
  22. 22.
    Brown ZA, Selke S, Zeh J, Kopelman J, Maslow A, Ashley RL, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med. 1997;337:509–15.PubMedCrossRefGoogle Scholar
  23. 23.
    Mooney MA, Janniger CK, Schwartz RA. Kaposi’s varicelliform eruption. Cutis. 1994;53: 243–5.PubMedGoogle Scholar
  24. 24.
    Kramer SC, Thomas CJ, Tyler WB, Elston DM. Kaposi’s varicelliform eruption: a case report and review of the literature. Cutis. 2004;73:115–22.PubMedGoogle Scholar
  25. 25.
    Anderson BJ. The epidemiology and clinical analysis of several outbreaks of herpes gladiatorum. Med Sci Sports Exerc. 2003;35:1809–14.PubMedCrossRefGoogle Scholar
  26. 26.
    Al-Dhafiri SA, Molinari R. Herpetic folliculitis. J Cutan Med Surg. 2002;6:19–22.PubMedCrossRefGoogle Scholar
  27. 27.
    Scott DA, Coulter WA, Lamey PJ. Oral shedding of herpes simplex virus type 1: a review. J Oral Pathol Med. 1997;26:441–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Aarnaes SL, Peterson EM, de la Maza LM. Evaluation of a new herpes simplex virus typing reagent for tissue culture confirmation. Diagn Microbiol Infect Dis. 1989;12(3):269–70.PubMedCrossRefGoogle Scholar
  29. 29.
    Strick LB, Wald A. Diagnostics for herpes simplex virus: is PCR the new gold standard? Mol Diagn Ther. 2006;10:17–28.PubMedCrossRefGoogle Scholar
  30. 30.
    Tateishi K, Toh Y, Minagawa H, Tashiro H. Detection of herpes simplex virus (HSV) in the saliva from 1,000 oral surgery outpatients by the polymerase chain reaction (PCR) and virus isolation. J Oral Pathol Med. 1994;23:80–4.PubMedCrossRefGoogle Scholar
  31. 31.
    Cone RW, Hobson AC, Palmer J, Remington M, Corey L. Extended duration of herpes simplex virus DNA in genital lesions detected by the polymerase chain reaction. J Infect Dis. 1991; 164:757–60.PubMedCrossRefGoogle Scholar
  32. 32.
    Nahass GT, Goldstein BA, Zhu WY, Serfling U, Penneys NS, Leonardi CL. Comparison of Tzanck smear, viral culture, and DNA diagnostic methods in detection of herpes simplex and varicella-zoster infection. JAMA. 1992;268:2541–4.PubMedCrossRefGoogle Scholar
  33. 33.
    Douglas D, Richman RJW, Hayden FG, editors. Clinical virology. Washington, DC: ASM Press; 2002.Google Scholar
  34. 34.
    Weedon D. Skin pathology. Edinburgh: Churchill Livingstone; 2002.Google Scholar
  35. 35.
    Derse D, Cheng YC, Furman PA, St Clair MH, Elion GB. Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate. Effects on primer-template function. J Biol Chem. 1981;256:11447–51.PubMedGoogle Scholar
  36. 36.
    Amir J, Harel L, Smetana Z, Varsano I. Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study. BMJ. 1997; 314(7097):1800–3.PubMedCrossRefGoogle Scholar
  37. 37.
    Thomas Kreig DRB, Miyachi Y, editors. Therapy of skin diseases: a worldwide perspective on therapeutic approaches and their molecular basis. London: Springer; 2010.Google Scholar
  38. 38.
    Spruance SL, Schnipper LE, Overall Jr JC, Kern ER, Wester B, Modlin J, et al. Treatment of herpes simplex labialis with topical acyclovir in polyethylene glycol. J Infect Dis. 1982;146:85–90.PubMedCrossRefGoogle Scholar
  39. 39.
    Reichman RC, Badger GJ, Mertz GJ, Corey L, Richman DD, Connor JD, Redfield D, Savoia MC, Oxman MN, Bryson Y, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. Treatment of recurrent genital herpes simplex infections with oral acyclovir. JAMA. 1984;251(16):2103–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Modi S, Van L, Gewirtzman A, Mendoza N, Bartlett B, Tremaine AM, Tyring S. Single-day treatment for orolabial and genital herpes: a brief review of pathogenesis and pharmacology. Ther Clin Risk Manag. 2008;4(2):409–17.PubMedGoogle Scholar
  41. 41.
    Rooney JF, Straus S, Mannix ML, Wohlenberg CR, Alling DW, Dumois JA, Notkins AL. Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial. Ann Intern Med. 1993;118(4):268–72.PubMedCrossRefGoogle Scholar
  42. 42.
    Baker D, Eisen D. Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies. Cutis. 2003;71(3):239–42.PubMedGoogle Scholar
  43. 43.
    Sacks SL, Thisted RA, Jones TM, Barbarash RA, Mikolich DJ, Ruoff GE, Jorizzo JL, Gunnill LB, Katz DH, Khalil MH, Morrow PR, Yakatan GJ, Pope LE, Berg JE, Docosanol 10% Cream Study Group. Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: a multicenter, randomized, placebo-controlled trial. J Am Acad Dermatol. 2001;45(2):222–30.PubMedCrossRefGoogle Scholar
  44. 44.
    Spruance SL, Nett R, Marbury T, Wolff R, Johnson J, Spaulding T. Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob Agents Chemother. 2002;46(7):2238–43.PubMedCrossRefGoogle Scholar
  45. 45.
    Glenny AM, Fernandez Mauleffinch LM, Pavitt S, Walsh T. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev. 2009;1, CD006706.PubMedGoogle Scholar
  46. 46.
    Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2011;55:459–72.PubMedCrossRefGoogle Scholar
  47. 47.
    Shiota T, Lixin W, Takayama-Ito M, Iizuka I, Ogata M, Tsuji M, et al. Expression of herpes simplex virus type 1 recombinant thymidine kinase and its application to a rapid antiviral sensitivity assay. Antiviral Res. 2011;91:142–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Anderson BJ. The effectiveness of valacyclovir in preventing reactivation of herpes gladiatorum in wrestlers. Clin J Sport Med. 1999;9:86–90.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of DermatologyThe University of Texas Medical School at HoustonHoustonUSA
  2. 2.Department of DermatologyThe University of Texas at HoustonHoustonUSA

Personalised recommendations